Evergreen Quality Fund GP Ltd. Sells 64,300 Shares of Abivax SA Sponsored ADR $ABVX

Evergreen Quality Fund GP Ltd. reduced its holdings in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) by 22.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 224,300 shares of the company’s stock after selling 64,300 shares during the period. Abivax comprises approximately 0.6% of Evergreen Quality Fund GP Ltd.’s portfolio, making the stock its 23rd biggest holding. Evergreen Quality Fund GP Ltd.’s holdings in Abivax were worth $30,248,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in ABVX. Bank of America Corp DE lifted its holdings in shares of Abivax by 56.1% in the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after acquiring an additional 1,990 shares during the last quarter. Cubist Systematic Strategies LLC grew its holdings in shares of Abivax by 34.3% during the 1st quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock valued at $63,000 after purchasing an additional 2,595 shares during the last quarter. Millennium Management LLC raised its position in Abivax by 6.0% in the 1st quarter. Millennium Management LLC now owns 987,414 shares of the company’s stock worth $6,171,000 after purchasing an additional 56,235 shares during the period. Woodline Partners LP raised its position in Abivax by 319.5% in the 1st quarter. Woodline Partners LP now owns 201,924 shares of the company’s stock worth $1,262,000 after purchasing an additional 153,788 shares during the period. Finally, XTX Topco Ltd bought a new stake in Abivax in the second quarter worth $139,000. 47.91% of the stock is owned by hedge funds and other institutional investors.

Abivax Trading Up 2.7%

Abivax stock opened at $100.15 on Thursday. The firm has a market cap of $7.99 billion, a P/E ratio of -19.22 and a beta of 0.69. Abivax SA Sponsored ADR has a 1-year low of $5.69 and a 1-year high of $148.83. The firm has a 50-day moving average of $114.81 and a 200-day moving average of $118.49.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings results on Friday, May 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.23. The business had revenue of $1.56 million for the quarter, compared to analysts’ expectations of $0.40 million. Research analysts forecast that Abivax SA Sponsored ADR will post -3.4 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on ABVX shares. Citigroup reaffirmed an “outperform” rating on shares of Abivax in a research note on Tuesday, June 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Abivax in a research note on Monday, April 20th. Wolfe Research set a $136.00 target price on Abivax in a report on Wednesday, June 3rd. Barclays raised their price target on Abivax from $142.00 to $148.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 24th. Finally, Oddo Bhf reiterated an “outperform” rating on shares of Abivax in a research report on Thursday, April 9th. Twelve equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $130.08.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.